Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimegepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.51 |
| ▸ | CALCA | P06881 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimegepant SCHEMBL24131009 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL1670580 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL29374210 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL2523699 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| Rimegepant SCHEMBL29592766 | 1.00 | CALCRL (1.00) | CALCRLADRB2CYP3A4RAMP1CALCA | |
| SCHEMBL30721761 | 0.97 | CALCRL (0.94) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL30563158 | 0.97 | CALCRL (0.94) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL29413909 | 0.96 | CALCRL (0.93) | CALCRLADRB2CYP3A4 | |
| Rimegepant SCHEMBL30064030 | 0.96 | CALCRL (0.93) | CALCRLADRB2CYP3A4 | |
| SCHEMBL30721794 | 0.96 | CALCRL (0.92) | CALCRLADRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488512-B1 | CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-11-27 | — | — | EP | claimed |
| US-8314117-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | claimed |
| EP-2488512-A1 | CGRP RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | claimed |
| WO-2011046997-A1 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | claimed |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | PFIZER IRELAND PHARMACEUTICALS (IE) | 2024-11-07 | — | — | US | disclosed |
| US-20230321066-A1 | PREVENTATIVE TREATMENT OF MIGRAINE | BIOHAVEN PHARMACEUTICAL IRELAND DAC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321066-A1 | PREVENTATIVE TREATMENT OF MIGRAINE | BIOHAVEN PHARMACEUTICAL IRELAND DAC (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023175632-A1 | SOLID STATE FORMS OF (5S,6S,9R)-5-AMINO-6-(2,3DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDIN-9-YL 4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)-1-PIPERIDINECARBOXYLATE HEMISULFATE AND PROCESSES FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175632-A1 | SOLID STATE FORMS OF (5S,6S,9R)-5-AMINO-6-(2,3DIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDIN-9-YL 4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)-1-PIPERIDINECARBOXYLATE HEMISULFATE AND PROCESSES FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-09-21 | — | — | WO | disclosed |
| US-20230285380-A1 | DUAL TREATMENT OF MIGRAINE | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285380-A1 | DUAL TREATMENT OF MIGRAINE | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20220168295-A1 | RIMEGEPANT FOR CGRP RELATED DISORDERS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-06-02 | — | — | US | disclosed |
| EP-2815749-A1 | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern | IP Gesellschaft für Management mbH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-8669368-B2 | Process for the preparation of cycloheptapyridine CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2488512-B1 | CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2013130402-A1 | N- (5S, 6S, 9R) - 5 -AMINO- 6 - (2, 3 - DIFLUOROPHENYL) -6, 7, 8, 9 - TETRAHYDRO - 5H - CYCLOHEPTA [B] PYRIDIN-9 -YL- 4 - (2 - OXO-2, 3 - DIHYDRO - 1H- IMIDAZO [4, 5 -B] PYRIDIN - 1 - YL) PIPERIDINE - 1 - CARBOXYLATE, HEMISULFATE SALT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130053570-A1 | CGRP Receptor Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-02-28 | — | — | US | disclosed |
| US-8314117-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120245356-A1 | Process for the Preparation of Cycloheptapyridine CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245356-A1 | Process for the Preparation of Cycloheptapyridine CGRP Receptor Antagonists | CALCRL, OPRL1, CALCR | CALCRL 1/4885ADRB2 140/4885CYP3A4 834/4885 |
| US-20240366618-A1 | CGRP Antagonists for Treating Trigeminal Neuralgia | OPRL1, CALCRL, CALCR | CALCRL 2/4885ADRB2 301/4885CYP3A4 4474/4885 |
| US-20220168295-A1 | RIMEGEPANT FOR CGRP RELATED DISORDERS | CALCRL, CALCA, CALCB | CALCRL 1/4885ADRB2 209/4885CYP3A4 3129/4885 |
| US-20130053570-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 44/4885CYP3A4 2984/4885 |
| US-20230285380-A1 | DUAL TREATMENT OF MIGRAINE | CALCB, PDE1A, PDE1B | CALCRL 7/4885ADRB2 306/4885CYP3A4 3113/4885 |
| US-20230321066-A1 | PREVENTATIVE TREATMENT OF MIGRAINE | PDE3A, CALCA, HTR5A | CALCRL 18/4885ADRB2 620/4885CYP3A4 3725/4885 |
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 44/4885CYP3A4 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.